-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Software Stocks Tied To Rising Compliance Spending

Simply Wall St·09/25/2026 11:25:32
语音播报

Global regulators are rewriting the rulebook on transparency, capital, and reporting, and that shift is quietly reshaping where risk and money sit. Compliance and risk software is moving from back-office cost to frontline necessity, which creates both potential winners and stocks that may be left behind. This article walks through 3 stocks exposed to this regulatory reset and explains how each could be helped or hurt as the new rules bite.

The three stocks discussed below are just a starting sample. The full screen surfaced 62 more companies with equally compelling narratives that are not covered in this article. To map that broader field and identify which regulatory tech stories fit your own checklist fastest, head straight into the Regulatory Compliance and Risk-Management Software Providers screener

Linedata Services (ENXTPA:LIN)

Linedata Services builds financial software that sits directly in the compliance and risk plumbing of asset managers, servicers, and lenders, from investment rule-checking and oversight to portfolio, fund accounting, and lending platforms. The business is relatively small at about €264 million in market value, which gives it a more focused exposure to rising regulatory spend.

Linedata Services provides targeted exposure to the rising cost and complexity of regulatory compliance, since its tools plug into investment rule monitoring, risk controls, and middle office workflows for banks and asset managers. The stock trades on a modest P/E versus many software peers, so much of the interest here rests on how one pressure on profitability plays out.

If you want to see whether that lower P/E is masking strength or fragility, you can go straight to the analysis report for Linedata Services for the full picture on Linedata Services.

ENXTPA:LIN P/E Ratio as at Sep 2026
ENXTPA:LIN P/E Ratio as at Sep 2026

ICRA (NSEI:ICRA)

ICRA is closely aligned with the regulatory compliance theme, turning credit ratings, risk analytics, and reporting tools into the infrastructure that helps banks and investors respond to tougher global rules. This positioning makes the firm a direct play on how this new regime is implemented.

ICRA earns about ₹3.46b from ratings and ancillary services and ₹2.96b from research and analytics, tying both sides of the business to risk assessment and regulatory-linked work. The stock is valued at roughly ₹42.76b in market cap.

"Sustained investments in technology, analytics, and automation are starting to enhance operational efficiency, lower unit costs, and allow ICRA to maintain high profitability even amidst margin pressures. This points to further margin expansion driven by operating leverage."

What matters now is how one less visible pressure on this regulatory analytics engine shapes pricing power and future demand.

That quiet pressure is already reshaping ICRA’s playbook, and the full narrative for ICRA shows how technology spending, regulation exposure, and competitive threats could be decoupling from the headline story.

NSEI:ICRA Revenue & Expenses Breakdown as at Sep 2026
NSEI:ICRA Revenue & Expenses Breakdown as at Sep 2026

Nomura Research Institute (TSE:4307)

Nomura Research Institute plugs directly into the screener theme through its financial IT solutions, supplying the systems that help banks and insurers handle risk, reporting, and complex regulatory requirements as those demands spread across borders and deepen for large institutions.

"The company’s new projects in Vietnam and additional investments in the U.S. indicate a strategic international expansion, enhancing the potential for increased operating revenue and profit from diversified geographic markets."

What really moves the needle is how one less visible pressure on profitability shapes the payoff from this growing compliance and risk workload.

That hidden profitability pressure is exactly where the real story for Nomura Research Institute starts to accelerate, so read the full narrative for Nomura Research Institute to see what might be getting overlooked.

TSE:4307 Revenue & Expenses Breakdown as at Sep 2026
TSE:4307 Revenue & Expenses Breakdown as at Sep 2026

Seeking Fresh Alternatives Before They Fly

Fresh regulatory stories are only part of the opportunity. New themes build momentum quickly, then get caught by the crowd. Scan what is still under the radar for now and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.